The estimated Net Worth of Russell Schundler is at least 5.16 百万$ dollars as of 30 August 2024. Mr Schundler owns over 2,344 units of Liquidia Corp stock worth over 4,966,740$ and over the last 4 years he sold LQDA stock worth over 191,797$.
Mr has made over 11 trades of the Liquidia Corp stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 2,344 units of LQDA stock worth 23,792$ on 30 August 2024.
The largest trade he's ever made was buying 117,908 units of Liquidia Corp stock on 10 November 2021 worth over 496,393$. On average, Mr trades about 12,473 units every 60 days since 2021. As of 30 August 2024 he still owns at least 489,334 units of Liquidia Corp stock.
You can see the complete history of Mr Schundler stock trades at the bottom of the page.
Russell Schundler is the Gen. Counsel & Corp. Sec. at Liquidia Corp.
Mr Schundler is 46, he's been the Gen. Counsel & Corp. Sec. of Liquidia Corp since . There are 17 older and 3 younger executives at Liquidia Corp. The oldest executive at Liquidia Corp is Ralph Snyderman, 80, who is the Independent Director.
Russell's mailing address filed with the SEC is 419 DAVIS DRIVE, SUITE 100, , MORRISVILLE, NC, 27560.
Over the last 6 years, insiders at Liquidia Corp have traded over 16,750,945$ worth of Liquidia Corp stock and bought 12,456,625 units worth 100,694,400$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of 1,467,274$. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth 23,792$.
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Liquidia Corp executives and other stock owners filed with the SEC include: